Literature DB >> 31609901

Anti-BAFF Treatment Interferes With Humoral Responses in a Model of Renal Transplantation in Rats.

Louisa Steines1, Helen Poth1, Antonia Schuster1, Edward K Geissler2, Kerstin Amann3, Bernhard Banas1, Tobias Bergler1.   

Abstract

BACKGROUND: B-cell-activating factor (BAFF) is associated with donor-specific antibodies (DSA) and poorer outcomes after renal transplantation (RTx). We examined the effects of anti-BAFF treatment on B cells, expression of costimulatory molecules and cytokines, germinal centers (GCs), and DSA formation in an RTx model in rats.
METHODS: Anti-BAFF antibody was injected on days 3, 17, 31, and 45 after allogeneic RTx. Rats received reduced dose cyclosporine A for 28 or 56 days to allow chronic rejection and DSA formation. Leukocytes, B-cell subsets, and DSA were measured using flow cytometry; expression of cytokines and costimulatory molecules was measured by quantitative polymerase chain reaction, and GCs and T follicular helper were assessed using immunohistochemistry. Rejection was evaluated by a nephropathologist.
RESULTS: Anti-BAFF treatment reduced the frequency of B cells in allografts and spleen. Naive B cells were strongly reduced by anti-BAFF treatment in all compartments. Messenger RNA expression of interleukin-6 and the costimulatory molecules CD40 and inducible T cell costimulator ligand was significantly reduced in anti-BAFF-treated rats. GC area was smaller and plasmablasts/plasma cell numbers lower in anti-BAFF-treated rats, which was reflected by less DSA in certain IgG subclasses.
CONCLUSIONS: Anti-BAFF treatment interferes with humoral responses at multiple levels in this model of allogeneic RTx.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31609901     DOI: 10.1097/TP.0000000000002992

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  Adaptive immune cell responses as therapeutic targets in antibody-mediated organ rejection.

Authors:  Kevin Louis; Camila Macedo; Carmen Lefaucheur; Diana Metes
Journal:  Trends Mol Med       Date:  2022-01-29       Impact factor: 11.951

2.  Anti-BAFF Therapy: A New Tool to Target B Cells in Antibody-mediated Rejection?

Authors:  Sarah E Panzer
Journal:  Transplantation       Date:  2020-01       Impact factor: 5.385

3.  B Cell Activating Factor (BAFF) Is Required for the Development of Intra-Renal Tertiary Lymphoid Organs in Experimental Kidney Transplantation in Rats.

Authors:  Louisa Steines; Helen Poth; Marlene Herrmann; Antonia Schuster; Bernhard Banas; Tobias Bergler
Journal:  Int J Mol Sci       Date:  2020-10-28       Impact factor: 5.923

4.  B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation.

Authors:  Antonia Margarete Schuster; N Miesgang; L Steines; C Bach; B Banas; T Bergler
Journal:  Immunol Res       Date:  2021-08-10       Impact factor: 2.829

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.